TransMedics Group (NASDAQ:TMDX) Receives Buy Rating from Canaccord Genuity Group

Canaccord Genuity Group reaffirmed their buy rating on shares of TransMedics Group (NASDAQ:TMDX) in a report issued on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a $142.00 target price on the stock.

Several other research firms have also issued reports on TMDX. Evercore ISI initiated coverage on TransMedics Group in a research note on Tuesday, September 16th. They set an “outperform” rating and a $155.00 price objective for the company. Morgan Stanley lifted their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a research note on Wednesday, October 8th. Stifel Nicolaus initiated coverage on TransMedics Group in a research note on Thursday, September 4th. They set a “hold” rating and a $115.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Monday, August 25th. Seven investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group has an average rating of “Moderate Buy” and an average price target of $127.18.

TransMedics Group Price Performance

TransMedics Group stock opened at $111.23 on Tuesday. TransMedics Group has a one year low of $55.00 and a one year high of $145.50. The business has a fifty day moving average price of $116.59 and a 200-day moving average price of $112.69. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The firm has a market capitalization of $3.79 billion, a P/E ratio of 57.63 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. The company had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%.The firm’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter last year, the company earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that TransMedics Group will post 1 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of TMDX. GAMMA Investing LLC increased its holdings in shares of TransMedics Group by 551.7% in the first quarter. GAMMA Investing LLC now owns 1,564 shares of the company’s stock worth $105,000 after buying an additional 1,324 shares during the period. SG Americas Securities LLC increased its holdings in shares of TransMedics Group by 132.2% in the first quarter. SG Americas Securities LLC now owns 14,126 shares of the company’s stock worth $950,000 after buying an additional 8,043 shares during the period. Janney Montgomery Scott LLC increased its holdings in shares of TransMedics Group by 129.9% in the first quarter. Janney Montgomery Scott LLC now owns 8,799 shares of the company’s stock worth $592,000 after buying an additional 4,972 shares during the period. Cornerstone Wealth Management LLC increased its holdings in shares of TransMedics Group by 68.5% in the first quarter. Cornerstone Wealth Management LLC now owns 6,247 shares of the company’s stock worth $420,000 after buying an additional 2,540 shares during the period. Finally, Abundance Wealth Counselors increased its holdings in shares of TransMedics Group by 22.0% in the first quarter. Abundance Wealth Counselors now owns 6,747 shares of the company’s stock worth $454,000 after buying an additional 1,218 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.